What Can PGT-A Address? Benefits and Limitations of Aneuploidy Testing
Genetic Testing

What Can PGT-A Address? Benefits and Limitations of Aneuploidy Testing

8 min readUpdated 2026-06-04

PGT-A may help identify some embryos with chromosomal aneuploidy, but it cannot guarantee pregnancy or fully predict embryo potential. Its value depends on patient age, embryo number and clinical context.

PGT-A is a type of preimplantation genetic testing used to assess whether embryos may have chromosomal aneuploidy, meaning missing or extra chromosomes. Aneuploidy may be associated with embryo developmental arrest, implantation failure, miscarriage or chromosomal disorders.

PGT-A is sometimes viewed as a way to select embryos, but it is not a universal screening tool for every IVF patient. Its value should be considered based on individual circumstances.

PGT-A usually requires embryo biopsy after the embryo reaches an appropriate stage. A small number of cells are tested in a genetics laboratory. Results may be reported as euploid, aneuploid, mosaic or no result. Because the tested sample represents only part of the embryo, interpretation requires caution.

PGT-A may be discussed in cases involving advanced reproductive age, recurrent pregnancy loss, repeated implantation failure or multiple embryos requiring transfer prioritization. However, discussion does not mean automatic recommendation.

Patients often ask whether PGT-A improves success rates. A careful answer is that PGT-A may help select embryos for transfer in some contexts, but it cannot guarantee pregnancy and does not change the underlying number or quality of embryos created. Evidence may vary by patient group.

Mosaic results can be complex. Mosaic embryos may contain cells with different chromosomal findings in the biopsy sample. Decisions about whether such embryos may be considered for transfer depend on many factors, including the laboratory report, patient circumstances, available embryos, counseling and local practice.

PGT-A cannot rule out all genetic diseases, cannot detect all monogenic conditions and cannot replace prenatal screening or diagnosis. Uterine factors, embryo biology, laboratory quality and clinical management still matter.

PGT-A is a useful but limited tool. It should be used with individualized counseling rather than as a routine default for all IVF patients. This article is for educational purposes only and does not constitute medical advice.

This article is published by the WFA knowledge editorial team for informational purposes only and does not constitute medical advice. Please consult a licensed healthcare provider in your jurisdiction for clinical guidance.